[
  {
    "ts": "2025-10-01T20:45:00+00:00",
    "headline": "Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease",
    "summary": "DUBLIN, October 01, 2025--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.",
    "url": "https://finance.yahoo.com/news/prothena-partner-bristol-myers-squibb-204500268.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "d0b52b6f-835d-3f57-a538-743a6672bda1",
      "content": {
        "id": "d0b52b6f-835d-3f57-a538-743a6672bda1",
        "contentType": "STORY",
        "title": "Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease",
        "description": "",
        "summary": "DUBLIN, October 01, 2025--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.",
        "pubDate": "2025-10-01T20:45:00Z",
        "displayTime": "2025-10-01T20:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/c0b932777c0276580cf9a50341122406",
          "originalWidth": 3612,
          "originalHeight": 1160,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Hw0O8GQeltDhC3AvvvQeLw--~B/aD0xMTYwO3c9MzYxMjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/c0b932777c0276580cf9a50341122406.cf.webp",
              "width": 3612,
              "height": 1160,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ffW9cUbFJw64dZvOb4gzww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c0b932777c0276580cf9a50341122406.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/prothena-partner-bristol-myers-squibb-204500268.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/prothena-partner-bristol-myers-squibb-204500268.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PRTA"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T19:43:36+00:00",
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index jumping 3.3% and th",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-194336811.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "a98cd658-08d8-305d-9160-86024b75eb82",
      "content": {
        "id": "a98cd658-08d8-305d-9160-86024b75eb82",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Rise Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Wednesday afternoon with the NYSE Health Care Index jumping 3.3% and th",
        "pubDate": "2025-10-01T19:43:36Z",
        "displayTime": "2025-10-01T19:43:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-194336811.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-194336811.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVS"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "UNH"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T19:19:00+00:00",
    "headline": "Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.",
    "summary": "The surge in pharmaceutical stocks that followed the administration’s deal with Pfizer on Tuesday was still going strong on Wednesday.",
    "url": "https://www.barrons.com/articles/trump-drug-stocks-pfizer-6a8aa31f?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "be2a290a-652d-3e48-ae36-557310b06f7c",
      "content": {
        "id": "be2a290a-652d-3e48-ae36-557310b06f7c",
        "contentType": "STORY",
        "title": "Trump Triggered a Rally in Drug Stocks. Why It Might Not Last.",
        "description": "",
        "summary": "The surge in pharmaceutical stocks that followed the administration’s deal with Pfizer on Tuesday was still going strong on Wednesday.",
        "pubDate": "2025-10-01T19:19:00Z",
        "displayTime": "2025-10-01T19:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/be2a290a-652d-3e48-ae36-557310b06f7c/trump-triggered-a-rally-in.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/1cbbfd6e5ed0c343851a1dea2ba7d567",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/31quULorKayYaCU8No40BA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/1cbbfd6e5ed0c343851a1dea2ba7d567.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cecNXeK4VQ0E0T5HWNryWw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/1cbbfd6e5ed0c343851a1dea2ba7d567.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/trump-drug-stocks-pfizer-6a8aa31f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T17:55:06+00:00",
    "headline": "Bristol Myers Squibb Adopts Veeva Systems Inc. (VEEV)’s Veeva Vault CRM, Boosting Market Confidence",
    "summary": "We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Veeva Systems Inc. is one of them. Veeva Systems Inc. (NYSE:VEEV), a leading provider of cloud-based software for the life sciences industry, continues to expand its influence through platforms such as Veeva Commercial Cloud, Data Cloud, and […]",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-adopts-veeva-175506340.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "32274801-8b13-39c7-9d14-fddef51f3581",
      "content": {
        "id": "32274801-8b13-39c7-9d14-fddef51f3581",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Adopts Veeva Systems Inc. (VEEV)’s Veeva Vault CRM, Boosting Market Confidence",
        "description": "",
        "summary": "We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. Veeva Systems Inc. is one of them. Veeva Systems Inc. (NYSE:VEEV), a leading provider of cloud-based software for the life sciences industry, continues to expand its influence through platforms such as Veeva Commercial Cloud, Data Cloud, and […]",
        "pubDate": "2025-10-01T17:55:06Z",
        "displayTime": "2025-10-01T17:55:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bcadb75ed28c9667fe0de75d55836b69",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Bristol Myers Squibb Adopts Veeva Systems Inc. (VEEV)'s Veeva Vault CRM, Boosting Market Confidence",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7_umXmEOQVpRc8ZZIDGC6g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/bcadb75ed28c9667fe0de75d55836b69.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K.105w_YPT__YkOtbEISrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bcadb75ed28c9667fe0de75d55836b69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-adopts-veeva-175506340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-adopts-veeva-175506340.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VEEV"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T16:21:15+00:00",
    "headline": "Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 5.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its experimental antibody, BMS-986446, for the treatment of early Alzheimer's disease. This special status was intended to help speed up the development and review of drugs that treat serious conditions where there is an unmet medical need. The drug candidate, which was in a mid-stage trial, aimed to slow or d",
    "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-162115834.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "a5d0fbc9-b5ad-32ec-8498-da4036cca74c",
      "content": {
        "id": "a5d0fbc9-b5ad-32ec-8498-da4036cca74c",
        "contentType": "STORY",
        "title": "Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today",
        "description": "",
        "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 5.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its experimental antibody, BMS-986446, for the treatment of early Alzheimer's disease. This special status was intended to help speed up the development and review of drugs that treat serious conditions where there is an unmet medical need. The drug candidate, which was in a mid-stage trial, aimed to slow or d",
        "pubDate": "2025-10-01T16:21:15Z",
        "displayTime": "2025-10-01T16:21:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BMY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gk.7_kJOBQAPS7VxEfLOgw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YM1F85oh4xO4w1Qalh6PGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-162115834.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-162115834.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "4502.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T14:01:24+00:00",
    "headline": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
    "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
    "url": "https://www.investors.com/news/technology/most-favored-nation-drug-prices/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "58d85c0f-e7ec-3b13-bd7c-7a16073d7c76",
      "content": {
        "id": "58d85c0f-e7ec-3b13-bd7c-7a16073d7c76",
        "contentType": "STORY",
        "title": "What TrumpRx Means For Controversial Plan To Lower U.S. Drug Prices",
        "description": "",
        "summary": "The White House unveiled TrumpRX as a key part of the administration's plan to lower U.S. drug prices. But serious questions remain.",
        "pubDate": "2025-10-01T14:01:24Z",
        "displayTime": "2025-10-01T14:01:24Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/58d85c0f-e7ec-3b13-bd7c-7a16073d7c76/what-trumprx-means-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/29d658a71bb617c0f5366b9311dc23e7",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4DwtVABZeJPzaaSPIAogAA--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/29d658a71bb617c0f5366b9311dc23e7.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3TcxCebGCiGOnair650fcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/29d658a71bb617c0f5366b9311dc23e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/most-favored-nation-drug-prices/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T10:59:00+00:00",
    "headline": "Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease",
    "summary": "PRINCETON, N.J., October 01, 2025--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-anti-mtbr-105900207.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "16b5b205-c11b-36e9-a639-08c813aa3d76",
      "content": {
        "id": "16b5b205-c11b-36e9-a639-08c813aa3d76",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease",
        "description": "",
        "summary": "PRINCETON, N.J., October 01, 2025--BMS's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease",
        "pubDate": "2025-10-01T10:59:00Z",
        "displayTime": "2025-10-01T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WVo30IUTCjBj1CKgk9FKPw--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LQ0A.MHYUHCX8pRquXMvOw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/001e8383b2984340af41c5bc422141c4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-anti-mtbr-105900207.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-anti-mtbr-105900207.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T10:30:00+00:00",
    "headline": "Pfizer’s Drug Price Deal with White House Gives Big Pharma a Booster Shot",
    "summary": "A 2024 RAND study found that US drug prices are 278% higher than in 33 other developed countries in the OECD.",
    "url": "https://www.thedailyupside.com/industries/healthcare/pfizer-drug-price-deal-with-white-house-bodes-well-for-pharma-stocks/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "3da899bc-1207-367e-9a4b-fc6d59c9655a",
      "content": {
        "id": "3da899bc-1207-367e-9a4b-fc6d59c9655a",
        "contentType": "STORY",
        "title": "Pfizer’s Drug Price Deal with White House Gives Big Pharma a Booster Shot",
        "description": "",
        "summary": "A 2024 RAND study found that US drug prices are 278% higher than in 33 other developed countries in the OECD.",
        "pubDate": "2025-10-01T10:30:00Z",
        "displayTime": "2025-10-01T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/85755059ae9bfa5ee63704693d796196",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of a Pfizer vaccine.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/duAEKLgG43Nl5mr1Gih6hg--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/85755059ae9bfa5ee63704693d796196.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UvtrJoFpOlNDRvQslRiiCw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/85755059ae9bfa5ee63704693d796196.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/industries/healthcare/pfizer-drug-price-deal-with-white-house-bodes-well-for-pharma-stocks/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-drug-price-deal-white-103000928.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-01T09:41:52+00:00",
    "headline": "Bristol Myers, Takeda to pool data for AI-based drug discovery",
    "summary": "By Sneha S K (Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist",
    "url": "https://ca.finance.yahoo.com/news/bristol-myers-takeda-pool-data-094152173.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "e220baf3-436d-3f0f-801f-1acf7c330696",
      "content": {
        "id": "e220baf3-436d-3f0f-801f-1acf7c330696",
        "contentType": "STORY",
        "title": "Bristol Myers, Takeda to pool data for AI-based drug discovery",
        "description": "",
        "summary": "By Sneha S K (Reuters) -Bristol Myers Squibb, Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist",
        "pubDate": "2025-10-01T09:41:52Z",
        "displayTime": "2025-10-01T09:41:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/ea4e2d0694384efe5be637fa93dbde00",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021.    REUTERS/Brian Snyder/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F1rOxW_4wvbhJDFbv3zRfw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/ea4e2d0694384efe5be637fa93dbde00.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MrMFJgbAFYJgMjettx3pKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/ea4e2d0694384efe5be637fa93dbde00.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/bristol-myers-takeda-pool-data-094152173.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-takeda-pool-data-094152173.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]